482 related articles for article (PubMed ID: 22813448)
1. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
Browning DJ; Kaiser PK; Rosenfeld PJ; Stewart MW
Am J Ophthalmol; 2012 Aug; 154(2):222-6. PubMed ID: 22813448
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.
Stewart MW
Expert Rev Clin Pharmacol; 2013 Mar; 6(2):103-13. PubMed ID: 23473589
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept for neovascular age-related macular degeneration.
Xu D; Kaiser PK
Immunotherapy; 2013 Feb; 5(2):121-30. PubMed ID: 23413903
[TBL] [Abstract][Full Text] [Related]
6. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration.
Papadopoulos Z
Eur J Ophthalmol; 2019 Jul; 29(4):368-378. PubMed ID: 30813810
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept in wet AMD: specific role and optimal use.
Semeraro F; Morescalchi F; Duse S; Parmeggiani F; Gambicorti E; Costagliola C
Drug Des Devel Ther; 2013; 7():711-22. PubMed ID: 23990705
[TBL] [Abstract][Full Text] [Related]
8. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
[TBL] [Abstract][Full Text] [Related]
9. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.
Dixon JA; Oliver SC; Olson JL; Mandava N
Expert Opin Investig Drugs; 2009 Oct; 18(10):1573-80. PubMed ID: 19694600
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.
Ohr M; Kaiser PK
Expert Opin Pharmacother; 2012 Mar; 13(4):585-91. PubMed ID: 22300011
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M
Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760
[TBL] [Abstract][Full Text] [Related]
12. Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion.
Evoy KE; Abel SR
Ann Pharmacother; 2013 Jun; 47(6):819-27. PubMed ID: 23673531
[TBL] [Abstract][Full Text] [Related]
13. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
[TBL] [Abstract][Full Text] [Related]
15. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Chong V
Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept for the treatment of neovascular age-related macular degeneration.
Verner-Cole EA; Davis SJ; Lauer AK
Drugs Today (Barc); 2012 May; 48(5):317-29. PubMed ID: 22645720
[TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.
Brown DM; Regillo CD
Am J Ophthalmol; 2007 Oct; 144(4):627-37. PubMed ID: 17893015
[TBL] [Abstract][Full Text] [Related]
18. Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration.
Mantel I; Gillies MC; Souied EH
Surv Ophthalmol; 2018; 63(5):638-645. PubMed ID: 29476754
[TBL] [Abstract][Full Text] [Related]
19. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
